(4 years, 10 months ago)
Lords ChamberI have a list of the current confirmed cases, which I am happy to place in the Library—it is probably not constructive to read it out—although the numbers are changing regularly. We are keeping travel advice and the monitoring of flights in and out of other Chinese cities under constant review. The advice at the moment is against all but essential travel to Wuhan. We will keep travel to other Chinese cities under close consideration.
My Lords, does my noble friend agree with one of the precepts of Darwinian medicine that there is generally a trade-off between virulence and contagiousness and that, in the world of viruses, if you want to spread by casual contact, it tends to help to keep the patient healthy and standing on their feet—as indeed I am with a cold at the moment? If this virus does spread from man to man—sorry, person to person—there is a chance that it may reduce in virulence and it is, therefore, important to keep in perspective the warnings that we give people. While we must not underreact to this, it is also important that we do not overreact and cause major disruption to the economy, as has occasionally happened with responses to previous incidences of influenza.
That was well put. Our view is that this is a proportionate and sensible response that is scalable and appropriate according to the evidence available. We will obviously be reviewing what is a new and emerging infection. Scientific understanding of the disease is evolving rapidly—essentially on a daily basis. We will obviously review the measures set out regularly.
It is important to set out what the symptoms are, in case anybody listening needs to understand. This is essentially a bad respiratory tract infection that could turn into pneumonia. At this stage around 2% of known cases have died. To compare mortality rates, SARS had one of 10% and Ebola 70%. That gives a level of perspective, but the picture is evolving and we will keep this under close review as the situation develops. Unsurprisingly, of course, within that context those at greatest risk are the vulnerable, the elderly or those with underlying health conditions, so the advice is to come forward if such symptoms occur.
(4 years, 10 months ago)
Lords ChamberThe noble Baroness is an avid campaigner on this, and I commend her on the work she does on it. I would be delighted to meet her to discuss this, of course, but I am also pleased with the progress we have made in bringing forward clinical trials to improve the evidence base around medicinal cannabis.
My Lords, my noble friend will be aware that this week sees the centenary of the prohibition amendment in the United States, a policy that resulted in disastrous health outcomes and a huge increase in criminality and was repealed within 10 years. Does she feel that history is being repeated with America’s policy of prohibiting vaping but not regulating it for product safety, resulting in a number of deaths caused by the illegal use of substances in vaping—contrasted with this country, where product safety regulation has enabled us to do safe vaping?
My noble friend has asked a comprehensive and pointed question. It is notable that e-cigarette use among young people in the United States has increased dramatically— 78% in high-school students and 48% in middle-school students. We have not seen that in the UK because of the very effective and tightly regulated methods we have brought in around advertising and access for under-18s, which have borne fruit. I am proud of the way in which we have managed that in the United Kingdom.
(5 years, 4 months ago)
Lords ChamberThe noble Baroness is correct to say that patients and clinicians have a right to expect their data to be held securely. Since the WannaCry attack in May 2017, we have taken steps to ensure that NHS security measures are of the highest standard. This includes £60 million to improve cyber resilience in local infrastructure, support for NHS organisations to update their Windows operating systems, procuring a new cybersecurity operations centre, and boosting the national capability to prevent, detect and respond to cyberattacks. We are also committed to achieving much greater operational visibility across all NHS digital systems. This is one of the ways in which we can respond to attacks. Lastly, we expect the highest ethical standards from all data-driven systems and that is why we have introduced the code of conduct for data-driven health and care technology. That is how we will ensure that we have some of the best AI and data-driven technologies.
My Lords, does my noble friend agree with one of the key points made by Professor Topol that one of the benefits of artificial intelligence is the “gift of time”, as he has put it? In other words, patients can spend more time with their doctor if certain more routine things are automated. Will my noble friend make sure that that is one of the key aims of bringing automation into healthcare?
My noble friend is right. One of the key recommendations is that by automating routine analyses such as radiology, diagnoses and pathology and routinely bringing in AI to sequence bed management, we will reduce the burden on clinicians so that they are able to see more patients. The review makes specific recommendations to help the workforce become more digital ready, which means increasing capacity and capability, and building the right environment. That is exactly what we have embedded into the NHS people plan and all that we are working on through NHSX.
(5 years, 7 months ago)
Lords ChamberTo ask Her Majesty’s Government what assessment they have made of the levels of smoking and incidence of lung cancer in Sweden as a result of steps taken by that government; and what plans Ministers have to visit that country as part of their forthcoming review of tobacco harm reduction.
My Lords, the current smoking rate in Sweden is 13%, compared to England where the rate is 14.9% and, across the UK, 15.1%. There are no current plans to visit Sweden. Smoking is at the lowest level recorded in England but we are not complacent and remain committed to reducing the rate to 12% or less by 2022, as outlined in the tobacco control plan for England.
My Lords, I thank my noble friend for that reply. She will be aware that the policy of harm reduction, whereby a less harmful new technology is used to displace a more harmful technology, was pioneered in this country by the noble Lord the Lord Speaker when he was Health Secretary in the 1980s with respect to needle exchanges and HIV. Such a policy has since proved effective in the introduction of e-cigarettes. However, in Sweden, the adult smoking rate is now down to 5% because of another harm-reduction technology, snus—the little teabag of snuff tobacco that one presses against one’s gum and is widely used in Sweden. As a result, there are low lung cancer rates in that country but, because snus is banned in the EU, we are currently unable to follow. Could we not save tens of thousands of lives if we were to legalise this technology when we left the EU at the end of next week?
I thank my noble friend for his question and join him in paying tribute to the noble Lord the Lord Speaker’s role in harm reduction. No tobacco product is safe to consume, due to its links to cancers. As my noble friend says, snus is banned under the EU tobacco products directive as an oral product, except in Sweden. We have made a commitment under the tobacco control plan that, following EU exit, the Government will consider reviewing the position on snus and whether the introduction of the product to the UK market would promote the kind of proportionate harm-reduction approach that he proposes. However, there is no evidence that snus in Sweden has reduced smoking rates, so the matter is very much under review.